(Q35557832)

English

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

scientific article published on 13 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 August 2017

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). (English)

1 reference

Europe PubMed Central

8 August 2017

1 reference

based on heuristic

inferred from title

28

object named as

Roland Veelken

1 reference

Europe PubMed Central

8 August 2017

Rebecca Fischer-Betz

11

object named as

Rebecca Fischer-Betz

1 reference

Europe PubMed Central

8 August 2017

Ulf Müller-Ladner

17

object named as

Ulf Müller-Ladner

1 reference

Europe PubMed Central

8 August 2017

Andrea Rubbert-Roth

13

object named as

Andrea Rubbert-Roth

1 reference

Europe PubMed Central

8 August 2017

Bernd C Kieseier

25

object named as

Bernd Kieseier

1 reference

Europe PubMed Central

8 August 2017

29

object named as

Ulf Ziemann

1 reference

Europe PubMed Central

8 August 2017

48

object named as

Heinz Wiendl

1 reference

Europe PubMed Central

8 August 2017

Hans-Peter Tony

1

object named as

Hans-Peter Tony

1 reference

Europe PubMed Central

8 August 2017

Christof Specker

0 references

Michael Sticherling

27

object named as

Michael Sticherling

1 reference

Europe PubMed Central

8 August 2017

37

object named as

Rüdiger Eming

1 reference

Europe PubMed Central

8 August 2017

38

object named as

Michael Hertl

1 reference

Europe PubMed Central

8 August 2017

Hendrik Schulze-Koops

3

object named as

Hendrik Schulze-Koops

1 reference

Europe PubMed Central

8 August 2017

author name string

Gerd Burmester

2

1 reference

Europe PubMed Central

8 August 2017

Mathias Grunke

4

1 reference

Europe PubMed Central

8 August 2017

Joerg Henes

5

1 reference

Europe PubMed Central

8 August 2017

Ina Kötter

6

1 reference

Europe PubMed Central

8 August 2017

Judith Haas

7

1 reference

Europe PubMed Central

8 August 2017

Leonore Unger

8

1 reference

Europe PubMed Central

8 August 2017

Svjetlana Lovric

9

1 reference

Europe PubMed Central

8 August 2017

Marion Haubitz

10

1 reference

Europe PubMed Central

8 August 2017

Gamal Chehab

12

1 reference

Europe PubMed Central

8 August 2017

Christof Specker

14

1 reference

Europe PubMed Central

8 August 2017

Jutta Weinerth

15

1 reference

Europe PubMed Central

8 August 2017

Julia Holle

16

1 reference

Europe PubMed Central

8 August 2017

Ramona König

18

1 reference

Europe PubMed Central

8 August 2017

Christoph Fiehn

19

1 reference

Europe PubMed Central

8 August 2017

Philip Burgwinkel

20

1 reference

Europe PubMed Central

8 August 2017

Klemens Budde

21

1 reference

Europe PubMed Central

8 August 2017

Helmut Sörensen

22

1 reference

Europe PubMed Central

8 August 2017

Michael Meurer

23

1 reference

Europe PubMed Central

8 August 2017

Martin Aringer

24

1 reference

Europe PubMed Central

8 August 2017

Cornelia Erfurt-Berge

26

1 reference

Europe PubMed Central

8 August 2017

Frank Strutz

30

1 reference

Europe PubMed Central

8 August 2017

Praxis von Wussow

31

1 reference

Europe PubMed Central

8 August 2017

Florian M P Meier

32

1 reference

Europe PubMed Central

8 August 2017

Nico Hunzelmann

33

1 reference

Europe PubMed Central

8 August 2017

Enno Schmidt

34

1 reference

Europe PubMed Central

8 August 2017

Raoul Bergner

35

1 reference

Europe PubMed Central

8 August 2017

Andreas Schwarting

36

1 reference

Europe PubMed Central

8 August 2017

Rudolf Stadler

39

1 reference

Europe PubMed Central

8 August 2017

Michael Schwarz-Eywill

40

1 reference

Europe PubMed Central

8 August 2017

Siegfried Wassenberg

41

1 reference

Europe PubMed Central

8 August 2017

Martin Fleck

42

1 reference

Europe PubMed Central

8 August 2017

Claudia Metzler

43

1 reference

Europe PubMed Central

8 August 2017

Uwe Zettl

44

1 reference

Europe PubMed Central

8 August 2017

Jens Westphal

45

1 reference

Europe PubMed Central

8 August 2017

Stefan Heitmann

46

1 reference

Europe PubMed Central

8 August 2017

Anna L Herzog

47

1 reference

Europe PubMed Central

8 August 2017

Waltraud Jakob

49

1 reference

Europe PubMed Central

8 August 2017

Elvira Schmidt

50

1 reference

Europe PubMed Central

8 August 2017

Klaus Freivogel

51

1 reference

Europe PubMed Central

8 August 2017

Thomas Dörner

52

1 reference

Europe PubMed Central

8 August 2017

GRAID investigators

53

1 reference

Europe PubMed Central

8 August 2017

publication date

13 May 2011

1 reference

Europe PubMed Central

8 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

8 August 2017

13

1 reference

Europe PubMed Central

8 August 2017

R75

1 reference

Europe PubMed Central

8 August 2017

3

1 reference

Europe PubMed Central

8 August 2017

https://scigraph.springernature.com/pub.10.1186/ar3337

0 references

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B cells as therapeutic targets in SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab in severe pemphigus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell-directed therapies for autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Mortality in systemic vasculitis: a systematic review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab for severe refractory pediatric Wegener granulomatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

A single cycle of rituximab for the treatment of severe pemphigus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Immune status and risk for infection in patients receiving chronic immunosuppressive therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

12 July 2018

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

The red wolf remains a wily foe.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab for peripheral ulcerative keratitis with wegener granulomatosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Recurrence of Wegener's granulomatosis with de novo intraoral presentation treated successfully with rituximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Prognosis and mortality of polymyositis and dermatomyositis patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218885

26 September 2018

Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids

1 reference

https://api.crossref.org/works/10.1186%2FAR3337

21 January 2018

Rituximab may form a complex with iGmÎº mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virusâ induced vasculitis

1 reference

https://api.crossref.org/works/10.1186%2FAR3337

21 January 2018

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two cases of refractory Wegener's granulomatosis successfully treated with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot trial of rituximab in the treatment of patients with dermatomyositis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in ANCA-associated disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

8 August 2017

Dimensions Publication ID

0 references

release_omthyp7bwnei3l2tkgtdwv3ngu

1 reference

https://api.fatcat.wiki/v0/release/omthyp7bwnei3l2tkgtdwv3ngu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35557832&oldid=2049961096"